By the way, why would a larger company want to acquire NSPH if nobody is buying the tests they have? After all, even with the multiple FDA-cleared tests they have they can barely scrape together enough buyers to generate $1M in product revenues.
RE: acquisition - that is an excellent point you raised. If sales demonstrated a pattern of strong growth, or they were offering unique products/tests that had no competitors (e.g. GENZ) or the performance was better than the competition: faster, more sensitive/accurate, then they MIGHT be an attractive acquisition target. But NSPH is in none of the positions, and they have no impact on the customer base due their low sales and placement numbers. Sure they broadly own their IP space, but if performance isn't better, they would not be an attractive acquisition target (IMHO). Others can say we are trashing the stock, but these are NSPH and the FDA's figures - so why are we labeled as trashers?
excellent concerns cited. sales force may be one issue. two, pipeline of FDA approved products makes the company more attract from acquisition proposition. three, you can't always look to the past performance and predict the future.
the trend is down for sure. so, give me your shares and i'll sell them back to you at $5+.
And once again one of the irrational pumpers on this board is kind enough to point out Credit Suisse's "guess" from two years ago about the pps....yet everything Credit Suisse predicted about this company has turned out to be false proselytizing.